Loading clinical trials...
Loading clinical trials...
A Multicenter, Open, Dose Increasing Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Primary Efficacy of xy0206 Tablets in Relapsed / Refractory Acute Myeloid Leukemia Subjects
Conditions
Interventions
XY0206
Locations
1
China
Institute of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Start Date
September 15, 2020
Primary Completion Date
February 1, 2024
Completion Date
February 1, 2024
Last Updated
May 18, 2023
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT06994676
NCT04628026
Lead Sponsor
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions